Biochemical and Stone-Risk Profiles With Topiramate Treatment Brian J. Welch, MD, Dion Graybeal, MD, Orson W. Moe, MD, Naim M. Maalouf, MD, Khashayar Sakhaee, MD  American Journal of Kidney Diseases  Volume 48, Issue 4, Pages 555-563 (October 2006) DOI: 10.1053/j.ajkd.2006.07.003 Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

Fig 1 Urinary pH and urinary citrate excretion (cross-sectional study). Horizontal lines indicate mean values. Hypocitraturia is defined as 24-hour urinary citrate excretion less than 320 mg/d.32-34 Abbreviation: TPM, topiramate. American Journal of Kidney Diseases 2006 48, 555-563DOI: (10.1053/j.ajkd.2006.07.003) Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

Fig 2 RSRs and undissociated uric acid excretion (cross-sectional study). Vertical bars, mean ± SD; white bars, control group; black bars, topiramate group. *P < 0.001 compared with the control group. American Journal of Kidney Diseases 2006 48, 555-563DOI: (10.1053/j.ajkd.2006.07.003) Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

Fig 3 Changes in (A) urinary pH and (B) urinary citrate excretion (milligrams per day) between baseline and after 3 months of topiramate treatment (short-term longitudinal study). Horizontal lines indicate mean values. Hypocitraturia is defined as 24-hour urinary citrate excretion less than 320 mg/d.32-34 Abbreviation: TPM, topiramate. American Journal of Kidney Diseases 2006 48, 555-563DOI: (10.1053/j.ajkd.2006.07.003) Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

Fig 4 Change in RSRs for (A) calcium oxalate and (B) brushite stones between baseline and after 3 months of topiramate treatment (short-term longitudinal study). Horizontal lines indicate mean values. Abbreviation: TPM, topiramate. American Journal of Kidney Diseases 2006 48, 555-563DOI: (10.1053/j.ajkd.2006.07.003) Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions